Cargando…
Correction to: Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
Autores principales: | Pestinger, Valerie, Smith, Matthew, Sillo, Toju, Findlay, John M., Laes, Jean‑Francois, Martin, Gerald, Middleton, Gary, Taniere, Phillipe, Beggs, Andrew D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363732/ https://www.ncbi.nlm.nih.gov/pubmed/32572786 http://dx.doi.org/10.1007/s40291-020-00479-2 |
Ejemplares similares
-
Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
por: Pestinger, Valerie, et al.
Publicado: (2020) -
The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden
por: Hallam, Sally, et al.
Publicado: (2020) -
Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study
por: Beggs, Andrew D., et al.
Publicado: (2018) -
Mechanisms of immunogenicity in colorectal cancer
por: Sillo, T O, et al.
Publicado: (2019) -
The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
por: Sillo, Toritseju O., et al.
Publicado: (2023)